论文部分内容阅读
目的探讨血清半胱氨酸蛋白酶抑制剂C(CystatinC)在感染HBV或HCV肝病患者中的临床应用。方法测定了207例HBV或者HCV感染的肝病患者和32名健康对照组(H组)中CystatinC和金属蛋白酶组织抑制剂(TIMPs)浓度。肝病患者被分成肝硬化组(A组,67例)、慢性乙肝组(B组,73例)、慢性丙肝组(C组,39例)和肝癌组(D组,28例)。结果受试者CystatinC、TIMP-1和TIMP-2在各组间差异均有统计学意义(F值分别为28.234、128.091、196.549,P值均<0.001)。CystatinC与TIMPs在各肝病组中的变化一致肝病组均显著高于健康对照组,A组和D组均显著高于B组与C组,A组与D组、B组与C组间均差异无统计学意义。Pearson相关分析显示CystatinC与TIMP-1在各肝病组中均呈明显正相关,且有显著性差异;但CystatinC与TIMP-2的相关性仅A组(r=0.269,P<0.05)和D组(r=0.398,P<0.05)呈正相关,有显著性差异,而B组(r=-0.102,P<0.05)和C组(r=-0.107,P<0.05)则呈负相关,且差异无统计学意义。结论血清胱抑素C可能是监测肝脏功能的有用指标。
Objective To investigate the clinical application of serum cystatin C in patients with HBV or HCV infection. Methods Serum levels of Cystatin C and TIMP were measured in 207 HBV-infected or HCV-infected liver patients and 32 healthy controls (group H). Liver disease patients were divided into cirrhosis group (A group, 67 cases), chronic hepatitis B group (B group, 73 cases), chronic hepatitis C group (C group, 39 cases) and liver cancer group (D group, 28 cases). Results The Cystatin C, TIMP-1 and TIMP-2 in the subjects were significantly different among the groups (F = 28.234, 128.091, 196.549, P <0.001). The changes of Cystatin C and TIMPs in all the liver disease groups were significantly higher than those in the healthy control group, the levels in group A and group D were significantly higher than those in group B and C, while those in group A and group D were significantly different No statistical significance. Pearson correlation analysis showed that there was a significant positive correlation between Cystatin C and TIMP-1 in each liver disease group, and there was a significant difference between them. However, the correlation between Cystatin C and TIMP-2 was only in group A (r = 0.269, P <0.05) (r = -0.102, P <0.05) and group C (r = -0.107, P <0.05), and there was a positive correlation between the two groups (r = 0.398, P < No statistical significance. Conclusions Serum cystatin C may be a useful indicator for monitoring liver function.